NCI10496
OPEN TO ACCRUAL
Ph 2 Study of Ipatasertib with Pembrolizumab for 1L Treatment of Recurrent or SCC of the H&N
NRGHN009
OPEN TO ACCRUAL
II/III Trial of Radiation w/ Cisplatin 100mg/m2 Q3W vs QW Cisplatin 40 mg2 for Pts w/ Loco Adv SCCHN
RTOG1216
OPEN TO ACCRUAL
PhII/III Cisplatin vs. Docetaxel-Cetuximab vs. Cisplatin-Atezolizumab for High Risk H&N
UW21120
OPEN TO ACCRUAL
Ph 1/2 Trial of Tipifarnib and Alpelisib in Recurrent/ Metastatic HNSCC
UW21144
OPEN TO ACCRUAL
Phase 1 + dose expansion of MSC in patients with Xerostomia post RT In H&N cancer
UW22118
OPEN TO ACCRUAL
A Pilot Window Study of Imatinib with Cetuximab newly dx H&N
UW22128
OPEN TO ACCRUAL
Ph 2 Study of Oral NRC-2694-A with Paclitaxel in Patients with Recurrent and/or Metastatic HNSCC
UW23121
OPEN TO ACCRUAL
Pilot Study of INCB081776